Performance in Initiating - Q2

Research Ethics Committee Reference Number	Name of Trial	Date of Receipt of Valid Research Application	Date of First Patient Recruited	Benchmark Met	Comments	Reasons for delay correspond to:
11/LO/0185	PROMIS Evaluation of Multi-Parametric Magnetic Resonance Imaging In The Diagnosis and Characterisation of Prostate Cancer	30/06/2014	02/10/2014	No	Delay in Radiology	Sponsor
11/EE/0347	ECST-2 The 2nd European Carotid Surgery Trial	12/04/2014		No	PI left the Trust	NHS Provider
13/LO/1686	ECLIPSE: Fovista™ and Lucentis® compared to Lucentis® alone in patients with AMD (Ophthotech) A Phase 3 randomised, double-masked, controlled trial to establish the safety and efficacy of intravitreous administration of Fovista™ (Anti PDGF-B pegylated aptamer) administered in combination with Lucentis® compared to Lucentis® monotherapy in subjects with subfoveal neovascular age-related macular degeneration.	28/05/2014	01/09/2014	No	Delay in provision of Pharmacy information by Sponsor	Sponsor

14/EM/0001	**TREND (CRFB002A2411) A 12-month, phase IIIb, randomized, visual acuity, assessor-masked, multicenter study assessing the efficacy and safety of ranibizumab 0.5mg in treat and extend regimen compared to monthly regimen, in patients with neovascular age-related macular degeneration**	**22/04/2014**	**02/06/2014**	**Yes**		**Neither**
13/LO/0733	**NCRN544 ADAPT AGS-003 + SOC in advanced RCC**	**18/08/2014**		**Within 70 Days**		**Neither**
13/NE/0197	**RDP Randomized trial of wide-field guided PRP for diabetic macular oedema (DMO) treated with Ranibizumab. (Ranibizumab for DMO PRP trial (RDP trial))**	**22/07/2014**		**Within 70 Days**		**Neither**
13/WM/0419	**MAMMO-50: Mammographic surveillance in breast cancer patients aged 50 years and over**	**18/08/2014**		**Within 70 Days**		**Neither**

13/WM/0491	**PROTEUS Prospective, randomized, multicentre, open label, phase II / III study to assess efficacy and safety of ranibizumab 0.5 mg intravitreal injections plus panretinal photocoagulation (PRP) versus PRP in monotherapy in the treatment of subjects with high risk proliferative diabetic retinopathy. (PROTEUS)**	**26/03/2014**	**31/07/2014**	**No**	**Poor recruiter nationally. Sponsor has extended the study on this basis.**	**Neither**
13/EM/0343	**COMPLETE A randomised, comparative effectiveness study of complete versus culprit-only revascularization strategies to treat multi-vessel disease after primary percutaneous coronary interventions for ST-segment elevation myocardial infarction.**	**26/09/2014**		**Within 70 Days**		**Neither**

13/LO/0145	**CLEOPATRA A multicentre phase III randomised controlled single masked clinical trial to test the clinical efficacy of Light Masks at preventing dark adaptation in the treatment of early diabetic macular oedema**	**16/04/2014**	**10/07/2014**	**No**	**Delay in administration of certification by Sponsor**	**Sponsor**
14/SC/0100	**JETREA FIRSTLINE (ALCON) - Assessment of Patients Treated With JETREA® for Vitreomacular Traction**	**06/05/2014**	**03/07/2014**	**Yes**		**Neither**
13/EE/0241	**CCRN 2278 - SIGNATURE Secukinumab in patients with moderate to severe active, chronic plaque psoriasis who have failed on TNFa antagonists: A clinical trial evaluating treatment results (SIGNATURE Study CAIN457AGB01)**	**26/06/2014**	**26/08/2014**	**Yes**		**Neither**
13/YH/0066	**Pressure-2 Pressure Relieving Support Surfaces: A Randomised Evaluation 2**	**18/08/2014**	**07/10/2014**	**Yes**		**Neither**

13/EM/0239	**RESPITE Remifentanil intravenous patient controlled analgesia (PCA) versus intramuscular pethidine for pain relief in labour: a randomised controlled trial**	**10/07/2014**		**No**		**Neither**
14/NW/0130	**RESPONSE (NT100) "A randomised, double blind, multi-center, placebo-controlled study to evaluate the efficacy, safety, and tolerability of NT100 in pregnant women with a history of unexplained recurrent pregnancy loss (RPL)."**	**10/07/2014**	**17/09/2014**	**Yes**		**Neither**
14/SC/0262	**SAFARI A phase IV, prospective, open label, uncontrolled, European study in patients with neovascular age-related macular degeneration (nAMD), evaluating the efficacy and safety of switching from intravitreal aflibercept to ranibizumab 05. mg : the SAFARI study.**	**04/09/2014**		**Within 70 Days**		**Neither**